Fitzgerald Kevin Joseph, who serves as CSO and EVP, Head of Research, has been an active seller of Alnylam Pharmaceuticals (ALNY) stock over the past month, with no corresponding open-market purchases during the same period. Across 95 total transactions spanning two companies, Joseph has disposed of approximately $11.33 million in shares while acquiring just under $45,000 in value, all of which came from a compensatory grant rather than a discretionary buy. The most recent activity, clustered between March 2 and March 5, 2026, shows 23 separate sale transactions in ALNY, with individual trade values ranging from roughly $8,960 to $231,408 and a combined total exceeding $1.3 million for that week alone.
The selling pattern is consistent and one-directional: every open-market transaction in the recent window is coded as an "S" sale, with no "P" purchase activity recorded. The largest single-day disposition occurred on March 3, when Joseph sold ALNY shares in four tranches totaling approximately $528,189, followed by another eight sales on March 4 worth roughly $194,508. The March 5 sales added approximately $213,177 across four additional tranches. The only non-sale transaction in the recent period was a March 2 award of ALNY shares valued at zero, which represents compensation rather than an investment decision.
Joseph's trading footprint also includes a single grant of OVID shares on April 7, 2026, valued at $44,999.68, though this appears to be an isolated award rather than part of an ongoing accumulation strategy. The overall picture is one of consistent monetization: Joseph has sold ALNY shares in 23 separate transactions over four trading days, with no purchases to offset the disposition. While the sales are relatively modest in size individually, the frequency and concentration suggest a deliberate reduction of his ALNY position, consistent with a senior executive diversifying holdings rather than expressing conviction through new buys.
AI-assisted summary